Vivos Therapeutics, Inc.
VVOS
$2.14
$0.010.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.47% | 8.91% | 0.54% | -9.23% | -17.70% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.47% | 8.91% | 0.54% | -9.23% | -17.70% |
| Cost of Revenue | 9.92% | 8.72% | -6.18% | -8.72% | -14.61% |
| Gross Profit | 9.15% | 9.04% | 5.19% | -9.57% | -19.72% |
| SG&A Expenses | -17.42% | -21.38% | -22.36% | -27.55% | -27.84% |
| Depreciation & Amortization | 3.20% | -6.59% | -8.72% | -11.54% | -12.92% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.91% | -15.74% | -19.71% | -24.49% | -25.80% |
| Operating Income | 29.67% | 35.40% | 34.99% | 35.72% | 31.42% |
| Income Before Tax | 28.17% | 18.02% | 18.46% | 35.77% | 22.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.17% | 18.02% | 18.46% | 35.77% | 22.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.17% | 18.02% | 18.46% | 35.77% | 22.63% |
| EBIT | 29.67% | 35.40% | 34.99% | 35.72% | 31.42% |
| EBITDA | 30.94% | 36.48% | 35.90% | 36.50% | 31.60% |
| EPS Basic | 81.36% | 70.86% | 56.60% | 61.46% | 49.37% |
| Normalized Basic EPS | 81.36% | 70.86% | 56.66% | 61.50% | 49.42% |
| EPS Diluted | 81.36% | 70.86% | 56.60% | 61.46% | 49.37% |
| Normalized Diluted EPS | 81.36% | 70.86% | 56.66% | 61.50% | 49.42% |
| Average Basic Shares Outstanding | 281.20% | 254.87% | 148.68% | 95.46% | 60.13% |
| Average Diluted Shares Outstanding | 281.20% | 254.87% | 148.68% | 95.46% | 60.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |